Trial · NCT03932799
Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing
NCT03932799, Completed, University of Washington; results first posted 2023-09-28
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing. Trials, record NCT03932799. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03932799
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing
- NCT number
- NCT03932799
- Status
- Completed
- Enrollment
- 5,411 participants, actual
- Lead sponsor
- University of Washington
- Conditions
- Opioid Use, Opioid-Related Disorders
- Interventions
- Prospective prior authorization (PA) with hard stops in Washington, Retrospective review (RR) with prescriber notification in Ohio
- First posted
- 2019-05-01
- Last updated
- 2023-09-28
- Results first posted
- 2023-09-28
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Subacute Phase - More Than 7 Days of Opioids | 6-12 weeks after injury | More than 7 unique days of opioids within the time period |
| Primary | Chronic Phase - Composite (Meeting ≥1 of the 3 Chronic Phase Metrics) | 3-6, 6-9, and 9-12 months after injury | At least 1 instance of either chronic opioid prescribing, concurrent opioid and sedative prescribing, or high dose opioid prescribing attributed to a worker within the time period |
| Primary | Chronic Phase - Chronic Opioids (≥60 Days' Supply) | 3-6, 6-9, and 9-12 months after injury | 60 or more unique days of opioids within the time period |
| Primary | Chronic Phase - Concurrent (Concurrent Sedatives/Hypnotics and Opioids on ≥1 Day) | 3-6, 6-9, and 9-12 months | At least 1 overlapping day of both a sedative and an opioid within the time period |
| Primary | Chronic Phase - High Dose (Average of ≥50 Morphine Equivalent Daily Dose [MEDD] Among All Days With Opioids) | 3-6, 6-9, and 9-12 months after injury | Mean MEDD of 50 or more during the days a worker received opioids (based on days' supply) within the time period |
| Secondary | ≥30% Decrease in Pain Intensity/Interference (PEG-3) | 12 months after injury | Clinically important improvement in pain intensity/interference defined as obtaining a ≥30% reduction in pain intensity and interference from baseline. This was assessed with the PEG-3, which is comprised of 3 items assessing pain intensity and pain interference with enjoyment of life/general activity on a 0 to 10 numerical rating scale (0 = no pain/does not interfere, 10 = pain as bad as you can imagine/completely interferes). 1 = ≥30% reduction in mean PEG-3 summary score from baseline; 0 = otherwise. |
| Secondary | Anxious Symptoms (PHQ-4) | 12 months after injury | 2-item PHQ-4 subscale assessed how often participant was bothered by anxious symptoms on 4-point scale (0 = not at all, 3 = nearly every day). 1 = summed subscale score ≥3; 0 = otherwise. |
| Secondary | Depressive Symptoms (PHQ-4) | 12 months after injury | 2-item PHQ-4 subscale assessing how often participant was bothered by depressive symptoms on 4-point scale (0 = not at all, 3 = nearly every day). 1 = summed subscale score ≥3; 0 = otherwise. |
| Secondary | Global Improvement (GIC) | 12 months after injury | Global Impression of Change on 7-point Likert scale. Participants asked to rate how they compared now to immediately after their injury (1 = very much improved, 7 = very much worse) 1 = "much improved" or "very much improved"; 0 = otherwise. |
| Secondary | Disability - Activity Limitation | 12 months after injury | Modified activity limitation items from the National Health Interview Survey (NHIS) 2011 Adult Functioning Supplement. Participants were asked to rate on a 3-point scale (limited a lot, limited a little, not limited at all) whether their health was limited in four domains: participating in leisure or social activities, getting out with friends or family, doing household chores such as cooking and cleaning, and using transportation to get to places you want to go. 1 = "limited a lot" ; 0 = otherwise. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Subacute Phase - More Than 7 Days of Opioids | 6-12 weeks after injury | % of participants | NUMBER | |
| PRIMARY | Chronic Phase - Composite (Meeting ≥1 of the 3 Chronic Phase Metrics) | 3-6, 6-9, and 9-12 months after injury | % of participants | NUMBER | |
| PRIMARY | Chronic Phase - Chronic Opioids (≥60 Days' Supply) | 3-6, 6-9, and 9-12 months after injury | % of participants | NUMBER | |
| PRIMARY | Chronic Phase - Concurrent (Concurrent Sedatives/Hypnotics and Opioids on ≥1 Day) | 3-6, 6-9, and 9-12 months | % of participants | NUMBER | |
| PRIMARY | Chronic Phase - High Dose (Average of ≥50 Morphine Equivalent Daily Dose [MEDD] Among All Days With Opioids) | 3-6, 6-9, and 9-12 months after injury | % of participants | NUMBER | |
| SECONDARY | ≥30% Decrease in Pain Intensity/Interference (PEG-3) | 12 months after injury | * Analysis performed within a distinct survey sample of workers~* Estimates for Washington (WA) have been survey-weighted; sampling weights for Ohio (OH) were always 1. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Anxious Symptoms (PHQ-4) | 12 months after injury | * Analysis performed within a distinct survey sample of workers~* Estimates for WA have been survey-weighted; sampling weights for OH were always 1. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Depressive Symptoms (PHQ-4) | 12 months after injury | * Analysis performed within a distinct survey sample of workers~* Estimates for WA have been survey-weighted; sampling weights for OH were always 1. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Global Improvement (GIC) | 12 months after injury | * Analysis performed within a distinct survey sample of workers~* Estimates for WA have been survey-weighted; sampling weights for OH were always 1. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Disability - Activity Limitation | 12 months after injury | * Analysis performed within a distinct survey sample of workers~* Estimates for WA have been survey-weighted; sampling weights for OH were always 1. | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 outcomesResults by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Subacute Phase - More Than 7 Days of Opioids | Washington | 1.9 | % of participants | ||
| Subacute Phase - More Than 7 Days of Opioids | Ohio | 12.2 | % of participants | ||
| Chronic Phase - Composite (Meeting ≥1 of the 3 Chronic Phase Metrics) | Washington | 3-6 months | 1.2 | % of participants | |
| Chronic Phase - Composite (Meeting ≥1 of the 3 Chronic Phase Metrics) | Ohio | 3-6 months | 2.4 | % of participants | |
| Chronic Phase - Composite (Meeting ≥1 of the 3 Chronic Phase Metrics) | Washington | 6-9 months | 0.9 | % of participants | |
| Chronic Phase - Composite (Meeting ≥1 of the 3 Chronic Phase Metrics) | Ohio | 6-9 months | 2.4 | % of participants | |
| Chronic Phase - Composite (Meeting ≥1 of the 3 Chronic Phase Metrics) | Washington | 9-12 months | 0.8 | % of participants | |
| Chronic Phase - Composite (Meeting ≥1 of the 3 Chronic Phase Metrics) | Ohio | 9-12 months | 2.1 | % of participants | |
| Chronic Phase - Chronic Opioids (≥60 Days' Supply) | Washington | 3-6 months | 0.0 | % of participants | |
| Chronic Phase - Chronic Opioids (≥60 Days' Supply) | Ohio | 3-6 months | 1.7 | % of participants |
1 to 10 of 58Source ClinicalTrials.gov
See all 58 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Washington | 4,632 | |
| Overall Study | STARTED | Ohio | 779 | |
| Overall Study | COMPLETED | Washington | 4,632 | |
| Overall Study | COMPLETED | Ohio | 779 | |
| Overall Study | NOT COMPLETED | Washington | 0 | |
| Overall Study | NOT COMPLETED | Ohio | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Washington | 0 | 0 |
| Total, all-cause mortality | Ohio | 0 | 0 |
| Total, other adverse events | Washington | 0 | 0 |
| Total, other adverse events | Ohio | 0 | 0 |
| Total, serious adverse events | Washington | 0 | 0 |
| Total, serious adverse events | Ohio | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons9
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Washington vs Ohio: Not Working for Pay | Trial comparisons |
| Washington vs Ohio: Global Improvement (GIC) | Trial comparisons |
| Washington vs Ohio: Problematic Opioid Use (TAPS) | Trial comparisons |
| Washington vs Ohio: Depressive Symptoms (PHQ-4) | Trial comparisons |
| Washington vs Ohio: Opioid Overdose/Adverse Effects | Trial comparisons |
| Washington vs Ohio: ≥30% Decrease in Pain Intensity/Interference (PEG-3) | Trial comparisons |
| Washington vs Ohio: Earning Less Than Before Injury | Trial comparisons |
| Washington vs Ohio: Anxious Symptoms (PHQ-4) | Trial comparisons |
| Washington vs Ohio: On Time Loss (Not Working) | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03932799
GET https://conductscience.org/api/trials/v1/NCT03932799/results?page=2